

# **CURRICULUM VITAE**

**Dr Doug Coyle**

**May 5, 2009**

a) NAME

Doug Coyle, associate professor, tenured  
Member of School of Graduate Studies and Research; yes  
Employee No: 96692

b) DEGREES

Master of Arts (Economics), University of Edinburgh, 1988  
Master of Science (Health Economics), University of York, 1990  
PhD (Economics), Brunel University, 2004

c) EMPLOYMENT HISTORY

1990-95 Research Fellow (equivalent rank to assistant professor), Centre for Health Economics, University of York, England  
1995-97 Associate Investigator, Clinical Epidemiology Unit, Ottawa Civic Hospital, Canada  
1995-97 Lecturer, Department of Medicine, University of Ottawa, Canada  
1995-97 Lecturer, Department of Epidemiology and Community Medicine, University of Ottawa, Canada  
1997-2000 Principal Investigator, Clinical Epidemiology Unit, Ottawa Civic Hospital, Canada  
1997-98 Adjunct Professor, Department of Medicine, University of Ottawa, Canada  
1997-98 Adjunct Professor, Department of Epidemiology and Community Medicine, University of Ottawa, Canada  
1998-2003 Assistant Professor, Department of Medicine, University of Ottawa, Canada  
1998-2003 Assistant Professor, Department of Epidemiology and Community Medicine, University of Ottawa, Canada  
2000-01 Senior Principal Investigator, Clinical Epidemiology Unit, Loeb Health Research Institute, Ottawa Hospital, Canada  
2001- Senior Scientist, Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa Hospital, Canada  
2003-2004 Associate Professor, Department of Medicine, University of Ottawa, Canada  
2003-2008 Associate Professor, Department of Epidemiology and Community Medicine, University of Ottawa, Canada  
2008- Professor, Department of Epidemiology and Community Medicine, University of Ottawa, Canada  
2009- Director, Graduate Studies Committee, Department of Epidemiology and Community Medicine

d) HONOURS

2005 Vice chancellor's prize for doctoral research, Brunel University  
2006 Article of the month: International Harm Reduction Association

e) SCHOLARLY AND PROFESSIONAL ACTIVITIES

National and International

- 2007-2006- Committee Member, College of Reviewers, Canada Research Chairs Program  
Member, Committee for the Evaluation of Drugs (formerly Drug Quality and Therapeutics Committee), Ontario Ministry of Health and Long Term Care
- 2008- Member, Drugs for Rare Diseases Working Group, Ontario Ministry of Health and Long Term Care
- 2005- Committee member, National Cancer Institute of Canada Working Group on Economic Analysis in Clinical Trials
- 1998- Scientific advisory panel member for the Canadian Coordinating Office of Health Technology Assessment
- 1995- Health economics advisor to the Cochrane Musculoskeletal Group
- 2006-2007 Member, Drug System Secretariat Working Group, Ontario Ministry of Health and Long Term Care
- 2007 Committee member, CIHR committee on Access to Quality Cancer Care
- 2005 Chair, CIHR, Sustainable Financing, Funding and Resource Allocation in Health Care: Options, Impacts and Public Expectations
- 2004-2006 Advisory committee to the Canadian Coordinating Office of Health Technology Assessment on the creation of the third edition of the Canadian economic evaluation guidelines.
- 2004-2006 Member, Ontario Health Technology Advisory Committee
- 2003-2005 Member, NCIC CTG Site chairs group
- 2003-2005 Chair, National Cancer Institute of Canada Working Group on Economic Analysis in Clinical Trials
- 2001-2004 Committee Member, CIHR, Health Services and Evaluations Research
- 2000 Invited Member, MRC, Clinical Trials
- 2000-2009 Coordination Committee of the Ulysses Project : International Program in Health Technology Assessment
- 1999-2003 Task Force Group of the Consensus on Health Economics Criteria-list Group
- 1997-2003 Committee member, National Cancer Institute of Canada Working Group on Economic Analysis in Clinical Trials.
- 1996-1998 Advisory committee to the Canadian Coordinating Office of Health Technology Assessment on the creation of a guidance document for costing health care interventions.
- 1994-1995 European School of Oncology working group on the cost-effectiveness of cancer care.

Local

- 2009- Member, Commission on the Sciences, University of Ottawa
- 2009- Member, Faculty of Medicine Graduate Studies Committee, Faculty of Medicine
- 2001- Member, Graduate Studies Committee, Department of Epidemiology and Community Medicine

2008-2009 Member, Equity, Diversity and Gender Committee, Department of Epidemiology and Community Medicine  
 2005-2009 Member, Department Teaching Personnel Committee, Department of Epidemiology and Community Medicine  
 2004-2009 Member, University of Ottawa Science scholarship committee  
 2003-2004 Member, Clinical Epidemiology Program, Senior Management Committee  
 1999-2001 Loeb Program Planning Committee  
 1995-2004 Member, Ottawa Hospital Research Ethics Board

f) GRADUATE SUPERVISION

Completed: 12 MSc, 1 MHA, 1 PhD

In progress: 5 MSc, 1 PhD

Name of students supervised within the past seven years

Jennifer Pennock (MSc) 1997-2002  
*The Cost of Not Breastfeeding*  
 Adrian Dalloo (MSc) 2000-2004  
*Can the Canadian Case Mix Age Group (0-17 yrs) Be Further Refined to Better Represent the Pediatric Population?*  
 Sophia Papadakis (MHA) 2002-2004  
*Economic Evaluation of Standard versus Distributed Cardiac Rehabilitation Program Delivery*  
 Michael King (MSc) 2002-2004  
*Managing the Risks from Residential Radon in Canada*  
 Kathryn O'Grady (MSc) 2003-2005  
*Effect of Neighbourhood Economic Characteristics on the Health of Individuals*  
 Li Chen (MSc) 2003-2005  
*A Comparison of Methods in the Presence of Censored Cost Data under Different Censoring Mechanisms*  
 Laura Hopkins (MSc) 2003-2004  
*CA-125 in the Surveillance of Patients with Ovarian Cancer: A Decision Model*  
 Elizabeth Fitzpatrick (PhD) 2005-2007  
*Parents Perspectives on the Impact of the Early Diagnosis of Childhood Hearing Loss*  
 Julia Frei (MSc) 2004-2007  
*The Provision of Newborn Screening: A Conjoint Analysis of Women's Preferences*  
 Phil Barnsley (MSc) 2004-2007  
*Evaluation of Surveillance Mammography Following Reconstructive Breast Surgery*  
 Michel Hadad (MSc) 2004-2008  
*Peri-operative Amiodarone in Cardiac Surgery Patients at High Risk for Post-Operative Atrial Fibrillation, Clinical and Economic Analysis*

g) TEACHING

UNDERGRADUATE TEACHING

2006- Lecture to 1<sup>st</sup> year medical students. Topic: Canadian Health Care System

## GRADUATE COURSES

### Coordinator

2000-2007 Concentration in Health Technology Assessment and Management  
MSc Epidemiology (University of Ottawa)

### Full courses

2006- Health Policy (EPI 7184)

1999- Health Economic Evaluation (EPI 5189)

2006-2007 Canadian health care system: organization and policy (HSR 6150)

2002-2008 Health Economic Evaluation: Ulysses Program

2001 Health Technology Assessment

1995-98 Health Technology Assessment and Economic Evaluation (EPI 5189)

1994-95 Diploma in Health Services Management (University of Hull)

Health economics module

1999 PhD Program in Health Studies (University of Waterloo): Research Practicum in Economic Analysis

### Individual Sessions

2001- MSc Epidemiology (University of Ottawa): Health Technology Assessment

1995- MSc Epidemiology (University of Ottawa): Advanced Clinical Trials

1996-97 MSc Health Administration (University of Ottawa): Health Economics

1994-95 MSc Health Economics (University of York) Health Economics

MSc Social Policy (University of York) Economics

MSc Health Services Research (Nuffield Institute) Health Economics

Diploma in Health Economics for Developing Countries (University of York)

Diploma in Health Economics for East European Countries (University of York)

## h) EXTERNAL RESEARCH FUNDING: Past 7 years

<u>Year</u>	<u>Source</u>	<u>Type</u>	<u>Amount per Year</u>	<u>Purpose</u>
2009-2010	PHAC PI: D. Coyle	C	\$46,500	Research
2008-2009	University of Alberta PI: D. Coyle	C	\$30,000	Research
2008	CADTH PI: D. Coyle	C	\$20,000	Research
2008	Eli Lilly	C	\$10,000	Research

2007-2008	PI:D Coyle CADTH	C	\$35,000	Research
2007	PI:D Coyle CADTH	C	\$40,000	Research
2007	PI:D Coyle CADTH	C	\$40,000	Research
2006-2007	PI:D Coyle CADTH	C	\$35,000	Research
2006-2010	PI: D Coyle CIHR	C	\$180,000	Research
2006-2007	PI: R. Sigal CCOHTA	C	\$30,000	Research
2006-2009	PI: D Coyle NCIC/CBCRA	C	\$150,000	Research
2006-2007	PI: E Grunfeld CCOHTA	C	\$99,000	Teaching
2005-2006	PI: P Lehaux CCOHTA	C	\$99,000	Teaching
2004	PI: P Lehaux BMS	O	\$35,000	Research
2003-2007	PI: D Coyle CIHR	C	\$200,000	Research
2003-2008	PI: I Stiell CIHR	C	\$46,000	Research
2003-2005	PI: B Wilson CIHR	C	\$115,000	Research
2003-2005	PI: J Grimshaw CIHR	C	\$87,000	Research
2002	PI: B Wilson BMS	O	\$35,000	Research
2001-2004	PI: D Coyle Ontario Neurotrauma Foundation	C	\$50,000	Research
2001-2003	PI: S Marshall CBCRI	C	\$85,000	Research
2001-2004	PI: L Paszat CIHR	C	\$90,000	Research
2001-2003	PI: D Anderson CIHR	C	\$60,000	Research
2001-2005	PI: B Hogg CIHR	C	\$55,000	Research
2001-2002	PI: R. Sigal CCOHTA	C	\$55,000	Research
2000-2003	PI: D Coyle Arthritis Society	C	\$65,000	Research
2002-2003	PI: P Tugwell Merck Frost	O	\$35,000	Research

2001-2002	PI D CI Eli Lilly Inc PI: D Coyle	O	\$50,000	Research
2001	Novartis Canada Inc PI: D Coyle	O	\$20,000	Research
2000-2001	Eli Lilly Inc PI: D Coyle	O	\$10,000	Research

i) INTERNAL RESEARCH FUNDING

j) PUBLICATIONS

Lifetime summary

Books edited :	1
Book chapters:	8
Papers in refereed journals:	113
Submitted articles:	5
Papers in refereed conference proceedings/Abstracts:	98
Technical Reports:	24
Others:	4

Details

Edited Books

1. Lunt N, **Coyle D** (eds.). Welfare and Policy: Research Agendas and Issues, London: Taylor Francis, 1996.

Book Chapters

1. Earle CC, **Coyle D**, Evans WK. Cost effectiveness and lung cancer. In Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD. Lung Cancer, Principles and Practice. Philadelphia: Lippincott Williams and Wilkins 2000.
2. **Coyle D**, Lee KM. Improving the evidence base of economic evaluations. In Donaldson C, Mugford M, Vale L. Evidence-based Health Economics London: BMJ 2002.
3. Earle CC, **Coyle D**, Evans WK. Cost effectiveness and lung cancer. In Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD. Lung Cancer, Principles and Practice. Philadelphia: Lippincott Williams and Wilkins 2000.
4. **Coyle D**. Cost-effectiveness of treating hypertension in the older adult. In: Scott AK. Hypertension in the Older Adult. London: Edward Arnold, 1997:148-160.

5. Small N, Ashwood A, **Coyle D**, Hennessey S, Jenkins-Clarke S, Rice N, Ahmedzai S. Palliative care in the community. In Hennessey D. Community Health Care Development, Basingstoke: MacMillan Press, 1997.
6. **Coyle D**, Godfrey C, Hardman G, Raistrick D. Unit costs of substance misuse services. In Netten A, Dennet J. Unit Costs of Community Care 1995, Kent: Personal Social Services Research Unit, 1995.
7. Drummond MF, **Coyle D**. Limitations of current economic evaluation methods in oncology. In Champey Y, Levy E. The Challenges in Studying the Socioeconomic Dimensions in Cancer Therapy, Pennsylvania: The Medicine Group USA, 1995.
8. **Coyle D**, Richardson G. The cost of back pain. In Clinical Standards Advisory Group. Epidemiology Review: The Epidemiology and Cost of Back Pain, London: HMSO, 1994.
9. **Coyle D**, Davies L. How to assess cost-effectiveness: elements of a sound economic evaluation. In: Drummond MF, Maynard A. Purchasing and providing cost-effective health care. Edinburgh: Churchill Livingstone, 1993:66-79.

#### Refereed Articles

1. Polisena J, **Coyle D**, Coyle K, McGill S. Home telehealth for chronic disease management: a systematic review and an analysis of economic evaluations. International Journal of Technology Assessment in Health Care 2009.
2. Gaboury I, O'Grady K, **Coyle D**, Le Saux N. Costing AOM: comparison of watch and wait versus amoxicillin. Paediatrics and Child Health 2009.
3. van Walraven C, Oake N, **Coyle D**, Taljaard M, Forster AJ. Changes in surrogate outcomes can be translated into clinical outcomes using a Monte Carlo model. Journal of Clinical Epidemiology 2009.
4. Potter BK, O'Reilly N, Etchegary H, Howley H, Graham ID, Walker M, **Coyle D**, Chorny Y, Cappelli M, Boland I, Wilson BJ. Exploring informed choice in the context of prenatal testing: findings from a qualitative study. Health Expect. 2008 11(4):355-65.
5. de Verteuil R, Imamura M, Zhu S, Glazener C, Fraser C, Munro N, Hutchison J, Grant A, **Coyle D**, Coyle K, Vale L. A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip. Health Technol Assess. 2008;12:1-244.
6. Paszat L, Sutradhar R, Grunfeld E, Gainford C, Benk V, Bondy S, **Coyle D** et al. Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series. Breast Cancer Res Treat. 2008 114(1):169-78.

7. Papadakis S, Reid RD, **Coyle D**, Beaton L, Angus D, Oldridge N. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex. *Eur J Cardiovasc Prev Rehabil*. 2008 Jun;15(3):347-353.
8. Etchegary H, Potter B, Howley H, Cappelli M, **Coyle D**, Graham I, Walker M, Wilson B. The influence of experiential knowledge on prenatal screening and testing decisions. *Genet Test*. 2008 12(1):115-24.
9. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, **Coyle D**, Tugwell P. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev*. 2008 (1).
10. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, **Coyle D**, Tugwell P. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev*. 2008 (1).
11. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, **Coyle D**, Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev*. 2008 (1).
12. Lauzier S, Maunsell E, Drolet M, **Coyle D**, Hébert-Croteau N, Brisson J. Wage losses in the year after breast cancer. *Journal of the National Cancer Institute J Natl Cancer Inst* 2008;100: 321–332
13. Fitzpatrick E, Angus D, Durieux-Smith A, Graham I, **Coyle D**. Parents' needs following identification of childhood hearing loss. *Am J Audiol*. 2008;17:38-49.
14. Hopkins ML, **Coyle D**, Le T, Fung MF, Wells G. Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model. *Curr Oncol*. 2007;14(5):167-72.
15. **Coyle D**, Rodby R, Soroka S, Levin A, Muirhead N, René de Cotret P, Chen R, Palmer A. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. *Clinical Therapeutics* 2007;29;1508-1523.
16. Sigal RJ, Kenny GP, Boulé NG, Wells GA, Prud'homme D, Fortier M, Reid RD, Tulloch H, **Coyle D**, Phillips P, Jennings A, Jaffey J Effects of aerobic exercise, resistance exercise, or both on glycemic control in type 2 diabetes: a randomized trial. *Annals of Internal Medicine* 2007;147(6):357-69.
17. Dong H, Buxton M, **Coyle D**. Value of information analysis for a new technology: computer assisted total knee replacement. *International Journal of Technology Assessment* 2007;223:337-342.

18. Fitzpatrick E, **Coyle D**, Durieux-Smith A, Graham ID, Angus D, Gaboury I. Parents' preferences for services for children with hearing loss: A conjoint analysis study. *Ear and Hearing* 2007;28(6):842-9.
19. **Coyle D**, Oakley J. Estimating the expected value of partial perfect information: a review of methods. *European Journal of Health Economics* 2008;9:251-9
20. Conterno LO, Shymanski J, Ramotar K, Toye B, van Walraven C, **Coyle D**, Roth VR. Real-time polymerase chain reaction detection of methicillin-resistant staphylococcus aureus: impact on nosocomial transmission and costs. *Infection Control and Hospital Epidemiology* 2007;28:1134-1141.
21. Stiell IG, Grimshaw J, Wells GA, **Coyle D**, Lesiuk HJ, Rowe BH, Brison RJ, Schull MJ, Lee J, Clement CM. A matched-pair cluster design study protocol to evaluate implementation of the Canadian C-spine rule in hospital emergency departments: Phase III. *Implement Sci.* 2007 Feb 8;2:4.
22. Barnsley P, **Coyle D**, Paszat L, Grunfeld E. Surveillance mammography following mastectomy and breast cancer reconstruction: a systematic review. *Plastic and Reconstructive Surgery* 2007;120:1125-1132.
23. Fitzpatrick E, Graham I, Durieux-Smith A, Angus D, **Coyle D**. Parents' perspectives on the impact of the early diagnosis of childhood hearing loss. *International Journal of Audiology* 2007 Feb;46(2):97-106
24. Grunfeld E, Levine MN, Julian JA, **Coyle D**, Szechtman B, Mirsky D, Verma S, Dent S, Sawka C, Pritchard KI, Ginsburg D, Wood M, Whelan T. A randomized trial of long term follow-up for early stage breast cancer: a comparison of family physician versus specialist care. *J Clin Oncol* 2006;24(6):848-55.
25. Podymow T, Turnbull J, **Coyle D**. Shelter-based palliative care for the homeless terminally ill. *Palliative Medicine* 2006;20:81-86.
26. Podymow T, Turnbull J, **Coyle D**, Yetisir E, Wells G. Shelter-based managed alcohol administration to chronically homeless people addicted to alcohol. *CMAJ.* 2006;174:45-9.
27. Cranney AB, **Coyle D**, Hopman WM, Hum V, Power B, Tugwell PS. Prospective evaluation of preferences and quality of life in women with hip fractures. *J Rheumatol.* 2005 Dec;32(12):2393-2399.
28. Cooper NJ, **Coyle D**, Abrams KR, Mugford M, Sutton AJ. Use of evidence in decision models: An appraisal of health technology assessments in the UK to date. *Journal of Health Services Research and Policy* 2005;10:245-50

29. Papadakis S, Oldridge NB, **Coyle D**, Mayhew A, Reid RD, Beaton L, Dafoe WA, Angus D. Economic evaluation of cardiac rehabilitation: a systematic review. *Eur J Cardiovasc Prev Rehabil*. 2005 Dec;12:513-520.
30. Ong MEH, **Coyle D**, Lim SH, Stiell I. Cost-effectiveness of hair apposition technique compared with standard suturing in scalp lacerations. *Ann Emerg Med*. 2005; 46:237-42.
31. El Saadany S, **Coyle D**, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention Results from a disease model. *Eur J Health Econ* 2005;6:159-165.
32. Lehoux P, Battista RN, Granados A, Gallo P, Tailliez S, **Coyle D** et al. International Master's Program in health technology assessment and management: Assessment of the first edition (2001–2003). *International Journal of Technology Assessment in Health Care* 2005;21:104–112.
33. Creery D, Iyer P, Samson L, **Coyle D**, Osborne G, MacDonald A. Costs associated with infant bronchiolitis in the Baffin region of Nunavut. *International Journal of Circumpolar Health* 2005; 64: 38-45.
34. Reid RD, Dafoe WA, Morrin L, Mayhew A, Papadakis S, Beaton L, Oldridge NB, **Coyle D**, Wells GA. Impact of program duration and contact frequency on efficacy and cost-effectiveness of cardiac rehabilitation: Results of a randomized trial. *American Heart Journal* 2005;149:862-868.
35. **Coyle D**, Barbeau M Cost effectiveness of elidel in the management of patients with atopic dermatitis in Canada. *Journal of Cutaneous Medicine and Surgery* 2004;8:405-410.
36. Amin M, Fergusson D, Wilson K, Aziz A, Tinmouth A, **Coyle D**, Hébert P, The societal unit cost of allogenic red cells and red cell transfusion in Canada. *Transfusion* 2004;44:1479-1486.
37. **Coyle D**, Rodby R. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. *Canadian Journal of Cardiology* 2004: 20:71-79.
38. Grunfeld E, **Coyle D**, Family caregiver burden: Results of a longitudinal study of breast cancer patients. *Can Med Assoc Journal* 2004;170:1795-1801.
39. Rodger MA, Gagne-Rodger C, Howley HE, Carrier M, **Coyle D**, Wells PS. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families compared to inpatient therapy. *Thrombosis Research* 2003;112:13-18.
40. Amin M, Fergusson D, Aziz A, Wilson K, **Coyle D**, Hebert P. The cost of allogeneic red blood cells – a systematic review. *Transfusion Medicine*, 2003;13:275–285.

41. **Coyle D**, Buxton MJ, O'Brien BJ. Measures of importance for economic analysis based on decision modeling. *Journal of Clinical Epidemiology* 2003;56:989-997.
42. Evans WK, **Coyle D**, Gafni A, Walker H. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Evaluation. *Chronic Dis Can.* 2003;24:102-7.
43. **Coyle D**, Tosteson ANA. Towards a reference case for economic evaluations of osteoporosis treatments. *J Rheumatol.* 2003;68s:31-6.
44. Spaans JN, **Coyle D**, Fodor G, Nair R, Vaillancourt R, Grover SA, Coupal L. Application of the 1998 Canadian cholesterol guidelines to a military population: health benefits and cost-effectiveness of improved cholesterol management *Canadian Journal of Cardiology* 2003;19:790-796.
45. **Coyle D**, Cranney A, Tugwell P. Economic evaluation of FemHRT for women with menopausal symptoms. *Pharmacoeconomics* 2003;21:661-669.
46. **Coyle D**, Steib D, Krewski D, Burnett R, Chen Y, DeCivita P, Thun M. Impact of particulate air pollution on quality adjusted life expectancy. *Journal of Toxicology and Environmental Health Part A.* 2003;66:1843-59.
47. Salvador A, Davies B, Fung Kee Fung K, Clinch J, **Coyle D**, Sweetman A. Program evaluation of hospital-based antenatal home care for high-risk women. *Hospital Quarterly* 2003.
48. Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetz A, **Coyle D** et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. *JAMA.* 2003;289:1941-1949.
49. **Coyle D**, Buxton MJ, O'Brien BJ. Stratified cost effectiveness analysis: a framework for establishing efficient limited use criteria. *Health Economics* 2003;12:421-427.
50. **Coyle D**, Barbeau M, Guttman M, Baladi J-F. The economic evaluation of pharmacotherapies for Parkinson's disease treatment. *Parkinson's and Related Disorders* 2003;9:301-307
51. Maetzel A, Tugwell P, Boers M, Guillemin F, **Coyle D**, Drummond M et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. *J Rheumatol.* 2003;30:891-6.
52. Gabriel S, Drummond M, Maetzel A, Boers M, **Coyle D**, Welch V et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. *J Rheumatol.* 2003;30:886-90.

53. Blumenauer B, Judd M, Cranney A, Burls A, **Coyle D**, Hochberg M, Tugwell P, Wells G. Etanercept for the treatment of rheumatoid arthritis. *Cochrane Database Syst Rev.* 2003;(4):
54. Earle CC, Grunfeld E, **Coyle D**, Cripps MC, Stern HS. Cancer physicians' attitudes toward colorectal cancer follow up. *Annals of Oncology* 2003;14:400-405.
55. Waldegger L, Cranney A, Hing M, Coyle D. Cost-effectiveness of hip protectors in institutional dwelling elderly. *Osteoporosis International* 2003;14: 243-250.
56. **Coyle D**, Grunfeld E, Wells GA. The assessment of the economic return from controlled clinical trials; a framework applied to clinical trials of colorectal cancer follow-up. *European Journal of Health Economics* 2003;4:6-11.
57. **Coyle D**, Graham ID. The role of economics in Canadian clinical practice guidelines of drug therapy. *Disease Management & Health Outcomes* 2003;1:45-48.
58. **Coyle D**. WHO's better not best: appropriate probabilistic uncertainty analysis. *International Journal of Technology Assessment in Health Care* 2003;19:540-545.
59. **Coyle D**. Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues. *Health Economics* 2003;12:159-162.
60. Blumenauer B, **Coyle D**, Tugwell P. Pharmacoeconomics of long-term treatment of rheumatoid arthritis. *Expert Opinion on Pharmacotherapy* 2002;3:417-22.
61. **Coyle D**, Palmer AJ, Tam R, Economic evaluation of PioglitazoneHCl in the management of Type 2 Diabetes Mellitus in Canada. *Pharmacoeconomics* 2002;20:31-42.
62. **Coyle D**, Lee KM, O'Brien BJ. The role of models within economic analysis: focus on Type 2 Diabetes. *Pharmacoeconomics* 2002;20:11-19.
63. Grunfeld E, Noorani H, McGahan L, Paszat L, **Coyle D**, van Walraven C, Joyce J, Sawka C. Surveillance mammography after treatment of primary breast cancer: a systematic review. *The Breast* 2002;11:228-235.
64. Gabriel SE, **Coyle D**, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. *Pharmacoeconomics* 2001; 19:715-728.
65. Stiell, I.G., Lesiuk, H., Wells, G.A., **Coyle, D.**, McKnight, R.D., Brison, R. et al. The Canadian CT Head Rule Study for Patients with Minor Head Injury: Methodology for Phase II (Validation and Economic Analysis). *Annals of Emergency Medicine*, 2001: 38; 317-322.

66. McKendrey RJ, **Coyle D**. Treatment related mortality versus quality of life - A balancing act. *J Rheumatol*. 2001;28:688-690.
67. **Coyle D**, Wells G, Graham I, Lee KM, Peterson J, Papadimitropoulos M. The impact of risk on preference values: implications for evaluations of postmenopausal osteoporosis therapy. *Value in Health* 2001;4: 185-191.
68. King WJ, Klassen TP, Bernard-Bonnin A-C, Robitaille Y, LeBlanc J, **Coyle D** et al. A randomized controlled trial examining the effectiveness of a home visit to prevent childhood. *Pediatrics* 2001; 108:382-388.
69. Gabriel SE, Drummond MF, **Coyle D**, Suarez-Almazor ME, Ruff B, Guillemin F, et al. OMERACT Economics Working Group: Summary, recommendations, and research agenda. *J Rheumatol* 2001;28:670-3.
70. **Coyle D**, Welch V, Shea B, Gabriel S, Drummond MF, Tugwell P. Issues of consensus and debate for economic evaluation in rheumatology *Journal of Rheumatology J Rheumatol* 2001;28:642-7.
71. **Coyle D**, Drummond MF. Analyzing differences in the costs of treatment across centres within economic evaluations. *International Journal of Technology Assessment in Health Care* 2001;17:155-163.
72. **Coyle D**, Cranney A, Lee KM, Welch V, Tugwell P. Cost-effectiveness of nasal calcitonin in postmenopausal women. Using Cochrane collaboration methods for meta analysis in economic evaluation. *Pharmacoeconomics* 2001; 19:565-575.
73. Cranney A, **Coyle D**,. Pham B. et al. The psychometric properties of patient preferences in osteoporosis. *J Rheumatol* 2001;28:132-7
74. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, **Coyle D**. et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. *Kidney International*. 2000; 58:1325-1335
75. Berthelot JM, Will BP, Evans WK, **Coyle D**, Earle CC, Bordeleau L. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. *Journal of the National Cancer Institute*.2000; 92:1321-1329.
76. **Coyle D**, Lee KM, Fergusson D, Laupacis A. Cost-effectiveness of epoetin- $\alpha$  to augment preoperative autologous blood donation in elective cardiac surgery. *Pharmacoeconomics* 2000;18:161-171.

77. Man-Son-Hing M, Laupacis A, O'Connor AM, **Coyle D**, Berquist R, McAlister F. Patient preference-based treatment thresholds: a comparison of decision analytic modeling with probability trade-off technique. *Medical Decision Making* 2000;20:394-403.
78. Petrou S, **Coyle D**, Fraser WD on behalf of the PEOPLE (Pushing Early or Pushing Late with Epidural) Study Group. Cost effectiveness of a delayed pushing policy under epidural anaesthesia. *American Journal of Obstetrics and Gynecology* 2000; 182(5): 1158-1164.
79. **Coyle D**, Cranney A, Lee KM, Welch V, Tugwell P. Cost effectiveness research in osteoporosis *Drug Discovery Research* 2000: 40:135-140.
80. **Coyle D**, Small N, Ashworth A, Hennesey S, Jenkins-Clarke S, Mannion R, Rice N, Ahmedzai S. Costs of palliative care in the community, in hospitals and in hospices in the UK. *Critical Reviews in Oncology Hematology* 1999;32:71-86.
81. Earle C, **Coyle D**, Smith A, Agboola O, Evans WK. The cost of radiotherapy at an Ontario regional cancer centre: a re-evaluation. *Critical Reviews in Oncology Hematology* 1999;32:87-94.
82. Cranney A, **Coyle D**, Welch V, Lee KM, Tugwell P. Current controversies in cost-effectiveness analysis of osteoporosis therapies. *Journal of Rheumatology* 1999; 25:2300-2302.
83. Cranney A, **Coyle D**, Welch V, Lee KM, Tugwell P. A review of economic evaluations in osteoporosis. *Arthritis Care Research* 1999 12:425-434.
84. Seguin J, Garber BC, **Coyle D**, Hebert PC. An economic evaluation of trauma care in a Canadian level 1 trauma hospital. *Journal of Trauma: Injury, Infection and Critical Care*. 1999;47:s99- s103.
85. **Coyle D**, Lee KM, Drummond MF. Comparison of alternative sources of data on health service encounters. *Journal of Health Services Research and Policy* 1999;4:210-214.
86. Grunfeld E, Gray A, Mant D, Yudkin P, Adewuyi-Dalton R, **Coyle D** et al. Follow-up of breast cancer in primary care vs. specialist care: results of an economic evaluation. *British Journal of Cancer* 1999;79:1227-1233.
87. Fergusson D, vanWalraven C, **Coyle D**, Laupacis A for the International Study of Peri-operative Transfusion (ISPOT) Investigators. Economic evaluation of technologies to minimize perioperative transfusion: A systematic review of published studies. *Transfusion Medicine Reviews* 1999;13:106-117.
88. **Coyle D**, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopedic surgery. *Transfusion Medicine* 1999;9:21-30.

89. Stewart DJ, Dahrouge S, **Coyle D**, Evans WK. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. *Journal of Clinical Oncology*. 17(1):344-351, 1999
90. Bailey AJ, Parmar MKB, Stephens RJ, CHART Steering Committee. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer. *Journal of Clinical Oncology* 1998, 16:3082-3093.
91. **Coyle D**, Lee KM. The problem of protocol driven costs in pharmacoeconomic analysis. *Pharmacoeconomics* 1998, 14:357-363.
92. Earle CC, **Coyle D**, Evans WK. Cost-effectiveness analysis in oncology. *Annals of Oncology* 1998, 9:475-482.
93. Drummond MF, **Coyle D**. The role of pilot studies in the economic evaluation of health technologies. *International Journal of Technology Assessment in Health Care* 1998, 14 405-418.
94. **Coyle D**, Davies LN, Drummond MF. Trials and tribulations: emerging issues in the design of economic evaluations alongside clinical trials. *International Journal of Technology Assessment in Health Care* 1998, 14:135-44.
95. **Coyle D**. Increasing demands to consider both the benefits and costs of cancer treatment in decision relating to resource allocation. *Cancer Prevention and Control* 1997, 1:277.
96. **Coyle D**, Drummond MF. Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer and carcinoma of the bronchus. *Clinical Oncology* 1997,9:313-321.
97. Agboola U, Grunfeld E, **Coyle D**, Perry G. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. *Canadian Medical Association Journal* 1997;157:879-886.
98. **Coyle D**, Godfrey C, Hardman G, Raistrick D. Costing substance misuse services. *Addiction* 1997;92(8):1007-1015.
99. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. *Lancet*, 1997, 350:161-165.
100. Chancellor J, **Coyle D**, Drummond MF. Constructing health state preference values: from descriptive quality of life outcomes: mission impossible? *Quality of Life Research* 1997, 6:159-168.

101. **Coyle D.** Statistical analysis in pharmacoeconomic studies: A review of current issues and standards. *Pharmacoeconomics* 1996, 9(6):506-516.
102. Saunders MI, Dische S, Barrett A, Parmar MKB, Harvey A, Gibson D et al. Randomised multicentre trials of CHART vs. conventional radiotherapy in head and neck and non-small-cell lung cancer. *British Journal of Cancer*, 1996, 73:1455-1462.
103. Dische S, Gibson D, Parmar M, Saunders MI et al. Time course from first symptom to treatment in patients with non-small cell lung cancer referred for radiotherapy: a report of the CHART Steering Committee. *Thorax* 1996, 51:1262-1265.
104. Williams C, **Coyle D**, Uyl-de-Groot C, et al. European School of Oncology Report to the Commission of the European Communities for the "Europe Against Cancer Programme": Cost-effectiveness in cancer care. *European Journal of Cancer*, 1995, 31A(9):1410-1424.
105. **Coyle D**, Drummond MF. The economic burden of glaucoma: the need for a far-sighted policy? *Pharmacoeconomics*, 1995;7:484-487.
106. Davies L, **Coyle D**, Drummond MF. Current status of economic appraisal in the European Community: Report of the network. *Social Science and Medicine*, 1994, 38(12):1601-1607.
107. Morris J, **Coyle D**. Quality of life questionnaires in cancer clinical trials: imputing missing values. *Psycho-Oncology*, 1994, 3:215-222.
108. Gibson D, Harvey AJ, Everett V, Parmar MKB et al. Is double data entry necessary? *Controlled Clinical Trials* 1994, 15: 482-488.
109. **Coyle D**. Economic evaluations of health. *Private Hospital Director Europe*, 1993, Summer:5-8.
110. **Coyle D**, Drummond MF. Does expenditure on pharmaceuticals good value for money?: current evidence and policy implications. *Health Policy*, 1993, 26(1):55-75.
111. **Coyle D**, Tolley K. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate? *Pharmacoeconomics*, 1992, 2(2):153-162.
112. Drummond MF, **Coyle D**. Assessing the economic value of anti-hypertensive medicines. *Journal of Human Hypertension*, 1992, 6:495-501.
113. Pekurinen M, Sintonen H, Pitkanen E, Alander V, **Coyle D**. Hospital productivity in Finland: further analysis. *Finnish Journal of Business Economics* 1991:1:50-67.

Refereed Conference Proceedings/Abstracts

1. Lauzier S, Maunsell E, Drolet M, Hébert-Croteau N, Brisson J, **Coyle D** et al. Financial burden from wage losses after early breast cancer: extent and determinants among Canadian women. American Society of Clinical Oncology, Chicago, IL: June 3, 2007
2. Barnsley GP, Grunfeld E, **Coyle D**, Paszat L. Evaluation of surveillance mammography following reconstructive breast surgery: A population based cohort study. Presented at the Canadian Society of Plastic Surgeons annual meeting, Banff Alberta, May 2007
3. **Coyle D**, O'Grady K, Julian JA, Szechtman B, Levine M, Grunfeld E. Cost effectiveness of strategies for the long term follow up for early stage breast cancer. *Med Decis Making*. 2007; 27:E20.
4. **Coyle D**, O'Grady K, Phillips P, Kenny G, Sigal R. Exercise programs for Type 2 diabetes: an economic analysis. *Med Decis Making*. 2007; 27:E9.
5. Barnsley GP, Grunfeld E, **Coyle D**, Paszat L. Evaluation of surveillance mammography following reconstructive breast surgery. Presented at the San Antonio Breast Cancer Symposium, December 2006
6. Barnsley GP, Grunfeld E, **Coyle D**, Paszat L. Surveillance mammography following the treatment of primary breast cancer with and without breast cancer reconstruction: a systematic review. Canadian Society of Plastic Surgeons annual meeting, Quebec City, Quebec, June 2006
7. De Maio VJ, **Coyle D**, Stiell IG, O'Grady K, Vaillancourt C, Nesbitt L, Wells GA. Location-specific cost effectiveness of Public Access Defibrillation, Society of Academic Emergency Medicine, San Francisco, May 2006.
8. O'Grady K, **Coyle D**, Wells GA. Effect of neighbourhood economic characteristics on the health of individuals. International Health Economics Association, Barcelona, July 2006.
9. Cooper N, **Coyle D**, Abrams K, Mugford M, Sutton A. Use of evidence in economic decision models: an application of health technology assessments in the UK since 1997. International Health Economics Association, Barcelona, July 2006.
10. **Coyle D**. Comparison of alternative methods for estimating partial EVPI in economic analysis. International Health Economics Association, Barcelona, July 2006.
11. **Coyle D**. Value of information analysis for the treatment of osteoporosis. International Health Economics Association, Barcelona, July 2006.
12. **Coyle D**, O'Grady K, De Maio VJ, Stiell IG. Location specific cost effectiveness of public access defibrillation. *Med Decis Making*. 2006; 26:E22.

13. Hopkins ML, **Coyle D**, Le T, Fung Kee Fung M, Wells G. CA-125 and ovarian cancer disease surveillance: A decision analysis based on societal perspective and cost effectiveness study. Society of Obstetrics and Gynecology of Canada, Quebec, Quebec, Canada, June 2005
14. Hopkins ML, **Coyle D**, Le T, Fung Kee Fung M, Wells G. A systematic review of the accuracy of CA-125 testing. Society of Obstetrics and Gynecology of Canada, Quebec, Quebec, Canada, June 2005
15. **Coyle D**. The impact of failure to calibrate on results in economic evaluation. *Med Decis Making*. 2005; 25:E32.
16. **Coyle D**. Comparison of methods for estimating partial EVPI in economic analysis. *Med Decis Making*. 2005; 25:E29.
17. Wells G, Suftan S, Chen L, **Coyle D**. Indirect Evidence: Indirect Treatment Comparisons in Meta-analysis. Current Issues for Health Technology Assessment in Canada: An Invitational Symposium for HTA Researchers and Policy Makers April 25-26, 2005.
18. Wilson B, Potter B, Chorny Y, Boland I, Graham I, Walker M, **Coyle D**. Women's perspectives on genetics: understanding, expectations and values. Proceedings of the Annual Meeting of the American Society of Human Genetics, 2004.
19. Chorny Y, Potter B, **Coyle D**, Graham I, Walker M, Wilson B. Understanding, Expectations and Values About Genetic Testing Among New Mothers. Proceedings of the Annual Qualitative Health Research Conference, 2004.
20. Wilson B, Chorny Y, Potter B, **Coyle D**, Graham I, Walker M. The Public and Genetics: Understanding, Expectations and Priorities. Proceedings of the GE3LS Symposium 2004
21. Grunfeld E, Levine M, Julian J, Pritchard K, Coyle D, Mirsky D, Verma S, Dent S, Sawka C, Ginsburg D. A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. *Journal of Clinical Oncology*, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S); 665.
22. Tellier A, Marshall SC, Wilson KG, Smith AM, Garber B, Stiell IG, **Coyle D**, O'Rourke K. Mild traumatic brain injury: The bias of sampling procedures and functional indices. *Proceedings of the International Neuropsychological Society*, 2004:169.
23. **Coyle D**. Using economic analysis to develop efficient limited use criteria: an application to treatments for osteoporosis. Meeting of the Society of Medical Decision Making 2003.
24. **Coyle D**, Stiell IG, Wells GA, Clement C. Bayesian economic analysis of the potential impact of the Canadian CT Head Rule. Meeting of the Society of Medical Decision Making 2003.

25. **Coyle D**, Barbeau M. Combining non parametric bootstrapping and Monte Carlo simulation in economic analysis: an application to the treatment of atopic dermatitis. Meeting of the Society of Medical Decision Making 2003.
26. **Coyle D**. Analyzing uncertainty and variability in economic evaluation: an application to the treatment of osteoporosis. Meeting of the International Health Economics Association. 2003;4:282-3.
27. **Coyle D**, Stiell IG, Wells GA, Clement C, for the CCC Study Group. Economic evaluation of the potential impact of the Canadian CT Head Rule. Acad Emerg Med 2003;10:554.
28. **Coyle D**, Stiell IG, Wells GA, Clement for the CCC Study Group. Economic evaluation of the potential impact of the Canadian CT Head Rule. Can J Emerg Med 2003;5:209.
29. Lauzier S, Maunsell E, Drolet M, **Coyle D**, Brisson J, Hebert-Croteau N. Costs to women during the first 6 months after a diagnosis of breast cancer. World Congress of Psycho-oncology 2003;6:320.
30. **Coyle D**, McIntyre L, Fergusson D, Hebert P. Economic analysis of the use of activated protein c in the treatment of severe sepsis in Canada. Meeting of the Society of Medical Decision Making 2002.
31. **Coyle D**, Stiell IG, Wells GA, Clement C. Economic evaluation of the potential impact of the Canadian C-Spine Rule. Acad Emerg Med 2002;9:455.
32. **Coyle D**, Stiell IG, Wells GA, Clement C, for the CCC Study Group. Economic evaluation of the potential impact of the Canadian C-Spine Rule. Can J Emerg Med 2002;4:139.
33. Grunfeld E, Whelan T, Reyno L, Earle C, Willan A, **Coyle D**, Foster G. Health service utilization in advanced breast cancer: frequency and predictors of unplanned acute care encounters (UACEs). American Society for Clinical Oncology Annual Meeting, 2002.
34. Grunfeld E, Whelan T, Reyno L, Earle C, Willan AR, **Coyle D**, Coristine M, Foster G. Sources of supportive care for women with advanced breast cancer. Supportive Care in Cancer Symposium, 2002.
35. Grunfeld E, Whelan T, Reyno L, Earle C, Willan AR, **Coyle D**, Coristine M, Foster G. Use of health services and supportive care services by women with advanced breast cancer towards the end of life: results of a longitudinal study. International Conference in Palliative Care, 2002.
36. **Coyle D**, Cranney A, Tugwell P. Decision analysis to assess the cost effectiveness of FemHRT for women with menopausal symptoms. Meeting of the Society of Medical Decision Making 2001.

37. **Coyle D**, Barbeau M, Baladi JF. Bayesian economic analysis of treatment with entacapone for Parkinson's Disease patients in Canada. Meeting of the Society of Medical Decision Making 2001.
38. **Coyle D**, Graham ID. The role of economic analysis in clinical guidelines relating to pharmaceuticals in Canada. Meeting of the International Health Economics Association. 2001;3: 110.
39. **Coyle D**, Grunfeld E, Wells GA. Using cost-effectiveness analysis in assisting in the design and prioritization of clinical trials: a case study of a potential trial of colorectal cancer follow-up regimens. Meeting of the International Health Economics Association. 2001;3: 158.
40. **Coyle D**, Lee KM. Improving the evidence base for economic analyses based on decision analysis. Meeting of the International Health Economics Association. 2001;3:177.
41. **Coyle D**, Graham ID. The role of economic analysis in clinical guidelines relating to pharmaceuticals in Canada. Meeting of the International Society of Technology Assessment in Health Care. 2001;17:15
42. **Coyle D**, Grunfeld E, Wells GA. Using cost-effectiveness analysis in assisting in the design and prioritization of clinical trials: a case study of a potential trial of colorectal cancer follow-up regimens. Meeting of the International Society of Technology Assessment in Health Care. 2001;17:15
43. Grunfeld E, Whelan T, **Coyle D**, Reyno L, Earle C, Willan A et al. Towards an understanding of the experiences of women with advanced breast cancer and the experiences of the principal family caregivers, Canadian Breast Cancer Research Initiative Conference 2001; 2;26.
44. Whelan T, Olivotto I, Ackermann I, Benk V, Vallis K, Nolan M et al. NCIC clinical trials group MA20: a randomized trial of regional nodal radiation in woman with early breast cancer. Canadian Breast Cancer Research Initiative Conference 2001; 2;51.
45. Grunfeld E, Levine M, Julian J, **Coyle D**, Dent S, Ginsburg D et al. A randomized trial of follow up strategies for breast cancer: acceptability of the study to patients, family physicians and specialists. Canadian Breast Cancer Research Initiative Conference 2001; 2;82.
46. Benk V, Paszat L, Bondy S, Grunfeld E, Shumak R, Sawka C et al. A population based case cohort study of the outcome of surveillance mammography after treatment for primary breast cancer. Canadian Breast Cancer Research Initiative Conference 2001; 2;89.
47. **Coyle D**, Grunfeld E, Whelan T, Willan A, Reyno L, Earle C et al. Financial burden on patient and caregivers due to advanced breast cancer. Canadian Breast Cancer Research Initiative Conference 2001; 2;94.

48. **Coyle D**, Palmer A. Economic evaluation of pioglitazone in the management of type 2 diabetes mellitus. *Canadian Journal of Clinical Pharmacology* 2001;8:18.
49. King WJ, Klassen TP, LeBlanc J, Bernard-Bonnin AC, Robitaille Y, Pham B, **Coyle D** et al. The effectiveness of a home visit to prevent childhood injury. *Pediatrics* 2001;107:1480-1.
50. **Coyle D**, Lee KM. Improving the evidence base for economic analyses based on decision analysis. Meeting of the International Society of Technology Assessment in Health Care. 2000;16:24
51. **Coyle D**, Bordeleau L, Earle CC, Will BP, Berthelot J-M, Evans WK. A decision-making framework for economic analyses: Using the example of advanced non-small cell lung cancer. Meeting of the International Society of Technology Assessment in Health Care. 2000;16:24
52. Lee KM, **Coyle D**, Baladi J-F. Transferring the results from economic evaluations: the use of basiliximab in transplant patients. *Value in Health* 2000; 3:105.
53. **Coyle D**, Lee KM. Improving the evidence base for economic analyses. *Value in Health* 2000; 3:106.
54. **Coyle D**, Cranney A, Lee KM, Welch V, Tugwell P. Cost-effectiveness of nasal calcitonin in postmenopausal women. Using Cochrane Collaboration methods in economic evaluation. *Seventh International Cochrane Colloquium* 1999;53.
55. Man-Son-Hing M, Laupacis A, O'Connor A, **Coyle D**, Berquist R, McAlister F. Preference-based treatment thresholds for patients: A comparison of probability trade-off technique and decision analytic modeling. *Medical Decision Making*, 19(4):519, 1999.
56. Lee KM, **Coyle D**, Buck D. The impact of new forms of patient information on the efficiency of health care delivery. Meeting of the International Health Economics Association. 1999;2; 260.
57. Cranney A, **Coyle D**. Commentary. *ACP Journal Club* 1999: 44.
58. **Coyle D**, Cranney A, Lee KM, Welch V, Tugwell P. Cost-effectiveness of nasal calcitonin in postmenopausal women. Using Cochrane Collaboration methods in economic evaluation. Annual Meeting of the International Society of Technology Assessment in Health Care. 1999;15:58
59. Wells GA, Earle CC, Pham B, Yetisir E, **Coyle D**. Assessment of methodologies to combine survival curves in meta-analysis: Applications to oncology. Annual Meeting of the International Society of Technology Assessment in Health Care. 1999;15:68.
60. **Coyle D**, Maunsell E, Wells GA, Graham I, Lee KM, Meunier N, Peterson JE. Differences in preference values between cultural groups: women's preferences over lifetime risks

associated with postmenopausal osteoporosis therapy. Annual Meeting of the International Society of Technology Assessment in Health Care. 1999;15:81.

61. Earle C, **Coyle D**, Wells GA, Papadimitropoulos E. .A needs based assessment of breast cancer in Canada: the economic burden of illness. Annual Meeting of the International Society of Technology Assessment in Health Care. 1999;15:87.
62. Cranney A, Welch V, **Coyle D**, Adachi JD, Tugwell P, Wells GA et al. Alendronate for prevention and treatment of postmenopausal osteoporosis. Annual Meeting of the International Society of Technology Assessment in Health Care. 1999;15:115.
63. **Coyle D**, Chun B, Berthelot JM, Houle C, Flanagan W. Population health model for determining the burden of disease associated with coronary heart disease in Canada. Annual Meeting of the International Society of Technology Assessment in Health Care. 1999;15:122.
64. Viola R, Moher D, **Coyle D**, Grunfeld E, Ross M, Claessens M, Weaver L, Lysne L, Larsen L, Scott J Synthesis of research evidence on the effects of palliative care services on family caregivers Journal of Palliative Care 1999; 15: 65.
65. Grunfeld E, Levine M, **Coyle D**, et al. A status report on a randomized trial of follow-up strategies for breast cancer. Canadian Breast Cancer Research Initiative Conference 1999.
66. Cranney A., Welch V., **Coyle D**, Adachi JD, Tugwell P, Wells GA et al. Cochrane review of alendronate for prevention and treatment of postmenopausal osteoporosis. Arthritis and Rheumatism, 1998;41: S134.
67. Wells GA, **Coyle D**, Lee KM, Foley RN, Parfrey PS, Morgan J et al. Quality of life effects of normalization of hemoglobin in asymptomatic hemodialysis patients. Journal of the American Society of Nephrology 1998;9:S277.
68. Stewart DJ, Dahrouge S, **Coyle D**, Evans WK. Impact of ondansetron on costs of preventing and treating nausea and vomiting. Proceedings of the American Society of Clinical Oncology, 1998, 17:270.
69. Cranney A, Welch V, Coyle D, Adachi JD, Tugwell P, Wells G et al. Alendronate for prevention and treatment of postmenopausal osteoporosis Sixth International Cochrane Colloquium 1998;95.
70. **Coyle D**, KM Lee, D Fergusson, A Laupacis. The cost effectiveness of erythropoietin to reduce perioperative blood transfusions in orthopedic surgery. Annual Meeting of the International Society of Technology Assessment in Health Care. 1998;14:
71. **Coyle D**, Wells G, Graham I, Lee KM, Peterson J, Papadimitropoulos M for the ABC Study Group. Women's preferences over lifetime risks of hip fracture, coronary heart disease and

breast cancer: implications for evaluations of postmenopausal osteoporosis therapy. Annual Meeting of the International Society of Technology Assessment in Health Care. 1998;14:

72. Grunfeld E, **Coyle D**. Transferability of the results of economic evaluations to different settings: the example of breast cancer follow up regimens. Annual Meeting of the International Society of Technology Assessment in Health Care. 1998;14:
73. **Coyle D**, Chun B, Berthelot JM, Houle C. Economic burden of coronary heart disease. Canadian Journal of Cardiology 1998.
74. Earle C, Coyle D, Graham ID, Wells GA, Papadimitropoulos M, Black D, Anxiety over Breast Cancer: A Population Survey. Presented to the Canadian Association of Medical Oncologists, Toronto, May 1998.
75. Graham I, **Coyle D**, Wells G, Earle C, Papadimitropoulos M for the ABC Study Group. Anxiety over breast cancer: a population survey. Menopause 1998.
76. **Coyle D**, Wells G, Graham I, Lee KM, Peterson J, Papadimitropoulos M for the ABC Study Group. Women's preferences over lifetime risks of hip fracture, coronary heart disease and breast cancer: implications for evaluations of postmenopausal osteoporosis therapy. Menopause 1998.
77. Cranney A, Pham B, **Coyle D**, Wells G, O'Connor A, Tugwell P. A pilot project of the validity of preferences in osteoporosis. Journal of Rheumatology 1998;25:s52.
78. **Coyle D**, Drummond MF. Multi-centre economic evaluation of CHART in the treatment of patients with head and neck cancer and carcinoma of the bronchus: Lessons for future studies. European Journal of Cancer 1997;33(S9):S19-S20.
79. **Coyle D**, Grunfeld E, Levine M, W K Evans. Methods for conducting economic analysis of the long-term management of breast cancer : description of two Canadian studies. European Journal of Cancer 1997;33(S9):S4.
80. Earle C, **Coyle D**, Smith A, Agboola O, Evans WK. The cost of radiotherapy at an Ontario regional cancer centre. European Journal of Cancer 1997;33(S9):S4.
81. Grunfeld E, Gray A, Mant D, **Coyle D**, Yudkin P, Fitzpatrick R, Vessey MP. Results of an economic evaluation of a RCT of routine follow-up after primary treatment for breast cancer: a comparison of primary care vs. specialist care. European Journal of Cancer 1997;33(S9):S5.
82. Small N, Ahmedzai S, **Coyle D**, Rice N, Ashworth A, Hennesey S, Jenkins-Clarke S, Mannion R, Mallet K. Costs and outcomes in UK palliative care services. European Journal of Cancer 1997;33(S9):S36.

83. Earle CC, Evans WK, Berthelot J-M, **Coyle D**, Roberge R, Will BP, Houle C. Cost-utility analysis of newer chemotherapy regimens for advanced non-small cell lung cancer. *Clinical and Investigative Medicine*. 1997;20(4) S58.
84. Earle CC, Evans WK, Berthelot J-M, Will BP, Houle C, **Coyle D**. Comparison of the costs, toxicities, and inconvenience of different chemotherapy regimens for advanced non-small cell lung cancer. *Lung Cancer* 1997;18(1):26
85. Hughes-Benzie R, Perras H, Graham I, **Coyle D**. Characteristics of a Canadian population at risk for hereditary colorectal cancer: Demographics, risk perception, anxiety and depression levels. *American Journal of Human Genetics* 1997; 61: 1088.
86. Chun B, **Coyle D**, Berthelot JM, Mustard C. Estimating the cost of coronary heart disease in Manitoba. *Proceedings of the American Statistical Association Joint Annual Meeting*. Chicago 1997.
87. Earle C, **Coyle D**, Logan D, Laupacis A. Can genetic testing cost-effectively target an intensive screening program for women with an inherited risk for breast cancer?. *Annual Meeting of International Society of Technology Assessment in Health Care*. 13:75, 1997.
88. Small N, Rice N, Ashworth A, **Coyle D**, Hennesey S, Jenkins-Clarke S, Ahmedzai S. The use of proxies in palliative care. *European Journal of Palliative Care* 1995; 87-88.
89. Drummond MF, **Coyle D**. The role of pilot studies in the economic evaluation of health technologies. *Annual Meeting of International Society of Technology Assessment in Health Care*. 12:31, 1996
90. **Coyle D**, Drummond M. Health technology assessment of conventional radical radiotherapy versus CHART for patients with head and neck cancer and carcinoma of the bronchus. *Annual Meeting of International Society of Technology Assessment in Health Care*. 12:19, 1996
91. Small N, Ashworth A, **Coyle D**, Hennesey S, Jenkins-Clarke S, Rice N, Ahmedzai S. Palliative care provision in the UK, findings of a study in 8 health districts. *European Journal of Palliative Care* 1995; 153-154.
92. Small N, Ashworth A, **Coyle D**, Hennesey S, Jenkins-Clarke S, Rice N, Ahmedzai S. Palliative care provision in the community: an analysis of variations in costs. *European Journal of Palliative Care* 1995; 154.
93. Rice N, Ahmedzai S, Ashworth A, **Coyle D**, Hennesey S, Jenkins-Clarke S, Small N. Palliative care in the community: an assessment of quality of life. *Quality of Life Research*, 1995, 4:478.
94. Chancellor J, **Coyle D**, Drummond M. Health state preferences in lung cancer. *Annual Meeting of International Society of Technology Assessment in Health Care*. 11: 71, 1995.

95. O'Connor A, Tugwell P, Carswell A, Ross M, Wells GA, Wolfson M, Dalziel W, Hing M, Angus D, Coyle D et al. Evidence-Based Decision Aids for Seniors. Presented to the Canadian Association of Gerontology Meeting, Vancouver, October 1995.
96. Davies LM, Drummond MF, Coyle D. Do economic evaluations of health technologies have an impact in decision making? Results of an EC survey. Annual Meeting of International Society of Technology Assessment in Health Care. 9:65, 1994.
97. Coyle D. Economic cost of asthma substantial in NSW. Pharmacoeconomics. 1(1):68-9, 1992.
98. Pekurinen M, Sintonen H, Alander V, **Coyle D**, Pitkanen E. Hospital productivity in Finland. in Health Systems - the Challenge of Change: Proceedings of the Fifth International Conference on System Science in Health Care. Prague: Omnipress 1992.

#### Technical Reports

1. Wells GA, Sultan SA, Chen L, Khan M, **Coyle D**. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
2. Membe SK, **Coyle D**, Husereau D, Cimon K, Tinmouth A, Normandin S. Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
3. Tran K, Polisena J, **Coyle D**, Coyle K, Kluge E-H W, Cimon K, McGill S, Noorani H, Palmer K, Scott R. Home telehealth for chronic disease management. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
4. Brown A, **Coyle D**, Cimon K, Farrah K. Hip protectors in long-term care: a clinical and cost-effectiveness review and primary economic evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
5. **Coyle D**, Coyle K, Vale L, de Verteuil R, Imamura M, Glazener C, Zhu S. Minimally Invasive Arthroplasty in the Management of Hip Arthritic Disease: Systematic Review and Economic Evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007
6. Tran K, Ho C, Noorani HZ, Cimon K, Hodgson A, **Coyle D**, Coyle K, Myers MG, Wright JM. Thiazide diuretics as first-line treatment for hypertension: meta-analysis and economic evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
7. **Coyle D**, Hadj Tahar A, Murphy G, Perras C, Skidmore B, Boucher M, Husereau D. Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and

- economic analysis [Technology report no 70]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
8. Wells GA, Cranney A, Boucher M, Peterson J, Shea B, Robinson V, **Coyle D**, Tugwell P. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no 69]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
  9. **Coyle D**, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P, Wells GA. Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation [Technology report no 64]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2006.
  10. Brown A, **Coyle D**, Chen S, Cumming D, Mensinkai S. Transdermal hormone replacement therapy patches for women with postmenopausal symptoms: economic analysis of short-term use [Technology report no 61]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2006.
  11. Mittmann N, Brown A, Seung SJ, **Coyle D**, Cohen E, Brophy J, Title L, Oh P. Economic evaluation of drug eluting stents [Technology report no 53]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005.
  12. Shukla VK, Otten N, **Coyle D**. Drug treatments for Alzheimer's disease. III. A review of pharmacoeconomic evaluations. Ottawa, CCOHTA 2000.
  13. R Viola, D Moher, D Coyle, E Grunfeld, M Ross, L Weaver, M Claessens, L Lysne, L Larsen, J Scott. Synthesis of Research Evidence on the Effects of Palliative Care Services on Family Caregivers Report to Health Canada, 1998.
  14. **Coyle D**, Lee KM, Fergusson DA, Laupacis A. The cost effectiveness of erythropoietin to reduce perioperative blood transfusions in surgery. Technical Document for CCOHTA, 1998.
  15. **Coyle D**, Lee KM. Inpatient costs of diabetic foot complications in Canada. Report to Brogan Incorporated 1998.
  16. Johnston K, **Coyle D**, Buxton MJ. An empirical example of the use of existing data to inform design. in Johnston K, Buxton MJ, Jones DR, Fitzpatrick R, Assessing the costs of health care technologies in clinical trials: issues in resource use data collection. Report to the Health Technology Assessment Programme 1997.
  17. A O'Connor, P Tugwell, A Carswell, M Ross, G Wells, M Wolfson, W Dalziel, M Hing, **D Coyle**, D Angus, W Hopman, T Elmslie, G Hollingworth, E Jolly, R McPherson, T MacKenzie. Evidence-based decision aids for seniors. Report to Health Canada 1997.

18. Ashwood A, **Coyle D**, Hennesey S, Jenkins-Clarke S, Rice N, Small N, Ahmedzai S. Standard Setting and Cost and Effectiveness in Palliative Care Services. Final Report. Report prepared for the UK Department of Health, July 1995.
19. **Coyle D**, Drummond MF, Morris J and Goddard M. Health technology assessment of continuous, hyperfractionated, accelerated radiotherapy (CHART): Comparison of CHART with conventional therapy in the treatment of patients with non-small cell carcinoma of the bronchus, Report to the UK Medical Research Council. April 1995.
20. **Coyle D**, Drummond MF, Morris J and Goddard M. Health technology assessment of continuous, hyperfractionated, accelerated radiotherapy (CHART): Comparison of CHART with conventional therapy in the treatment of patients with cancer of the head and neck, Report to the UK Medical Research Council. April 1995.
21. **Coyle D**, Richardson G. Modelling the effects of management guidelines and service recommendations on resource use. Report to the Clinical Standards Advisory Group Committee on Back Pain. February 1994.
22. **Coyle D**, Richardson G. The cost of back pain. Report to the Clinical Standards Advisory Group Committee on Back Pain. February 1994.
23. Rudat K, Ivins C, Carr-Hill R, and **Coyle D**. Housing and Health, Report prepared for the UK Department of Environment. December 1993.
24. Drummond MF, **Coyle D**. Examples of improved value for money from the use of pharmaceuticals. Report to IFPMA Goring Group. November 1992.

#### Others

1. Wells GA, Sultan SA, Chen L, Khan M, **Coyle D**. Indirect treatment comparison [computer program]. Version 1.0. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
2. **Coyle D**, Godfrey C, Hardman G, Raistrick D. Costing substance misuse services. York: YARTIC Occasional Paper 5, 1994.
3. **Coyle D**. Increasing the impact of economic evaluations on health-care decision-making. York: Centre for Health Economics Discussion Paper 108, 1993.
4. Morris J, Goddard M, **Coyle D**, Drummond M. Measuring cost and quality of life in radiotherapy treatments. York : Centre for Health Economics Discussion Paper 112, 1993.

SIGNATURE:

DATE: May 11, 2009